Monica Raimo

Dr. Monica Raimo

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
NLNina Lamers-Kok
Nina Lamers-Kok
DPDenise Panella
Denise Panella
AGAnna-Maria Georgoudaki
Anna-Maria Georgoudaki
HLHaiping Liu
Haiping Liu
DÖDidem Özkazanc
Didem Özkazanc
MRMonica Raimo
Monica Raimo
Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct recognition of surface ligands, without prior sensitization. Allogeneic NK transfer is a highly valuable treatment option for cancer and has recently emerged with hundreds of clinical trials paving the way to finally achieve market authorization. Advantages of NK cell therapies include the use of allogenic cell sources, off-the-shelf availability, and no risk of graft-versus-host disease (GvHD). Allogeneic NK cell therapies have reached the clinical stage as ex vivo expanded and differentiated non-engineered cells, as chimeric antigen receptor (CAR)-engineered or CD16-engineered products, or as combination therapies with antibodies, priming agents, and other drugs. This review summarizes the recent clinical status of allogeneic NK cell-based therapies for the treatment of hematological and solid tumors, discussing the main characteristics of the different cell sources used for NK product development, their use in cell manufacturing processes, the engineering methods and strategies adopted for genetically modified products, and the chosen approaches for combination therapies. A comparative analysis between NK-based non-engineered, engineered, and combination therapies is presented, examining the choices made by product developers regarding the NK cell source and the targeted tumor indications, for both solid and hematological cancers. Clinical trial outcomes are discussed and, when available, assessed in comparison with preclinical data. Regulatory challenges for product approval are reviewed, highlighting the lack of specificity of requirements and standardization between products. Additionally, the competitive landscape and business field is presented. This review offers a comprehensive overview of the effort driven by biotech and pharmaceutical companies and by academic centers to bring NK cell therapies to pivotal clinical trial stages and to market authorization.

21 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AVAmanda van Vliet
Amanda van Vliet
AGAnna-Maria Georgoudaki
Anna-Maria Georgoudaki
MRMonica Raimo
Monica Raimo
TGTanja De Gruijl
Tanja De Gruijl
JSJan Spanholtz
Jan Spanholtz
Adoptive cell therapy (ACT) represents a promising alternative approach for patients with treatment-resistant metastatic melanoma. Lately, tumor infiltrating lymphocyte (TIL) therapy and chimeric antigen receptor (CAR)-T cell therapy have shown improved clinical outcome, compared to conventional chemotherapy or immunotherapy. Nevertheless, they are limited by immune escape of the tumor, cytokine release syndrome, and manufacturing challenges of autologous therapies. Conversely, the clinical use of Natural Killer (NK) cells has demonstrated a favorable clinical safety profile with minimal toxicities, providing an encouraging treatment alternative. Unlike T cells, NK cells are activated, amongst other mechanisms, by the downregulation of HLA class I molecules, thereby overcoming the hurdle of tumor immune escape. However, impairment of NK cell function has been observed in melanoma patients, resulting in deteriorated natural defense. To overcome this limitation, “activated” autologous or allogeneic NK cells have been infused into melanoma patients in early clinical trials, showing encouraging clinical benefit. Furthermore, as several NK cell-based therapeutics are being developed for different cancers, an emerging variety of approaches to increase migration and infiltration of adoptively transferred NK cells towards solid tumors is under preclinical investigation. These developments point to adoptive NK cell therapy as a highly promising treatment for metastatic melanoma in the future.

2 September 2024 in Molecular Therapy Oncology
Verified
Journal Article
Open access
AVAmanda van Vliet
Amanda van Vliet
MHMirjam G.C.N. van Den Hout
Mirjam G.C.N. van Den Hout
DSDaniëlle Steenmans
Daniëlle Steenmans
ADAdil D. Duru
Adil D. Duru
AGAnna-Maria Georgoudaki
Anna-Maria Georgoudaki
MRMonica Raimo
Monica Raimo
Allogeneic natural killer (NK) cell therapies are a valuable treatment option for cancer, given their remarkable safety and favorable efficacy profile. Although the use of allogeneic donors allows for off-the-shelf and timely patient treatment, intrinsic interindividual differences put clinical efficacy at risk. The identification of donors with superior anti-tumor activity is essential to ensure the success of adoptive NK cell therapies. Here, we investigated the heterogeneity of 10 umbilical cord blood stem cell-derived NK cell batches. First, we evaluated the donors' cytotoxic potential against tumor cell lines from solid and hematological cancer indications, to distinguish a group of superior, "excellent" killers (4/10), compared with "good" killers (6/10). Next, bulk and single-cell RNA sequencing, performed at different stages of NK differentiation, revealed distinct transcriptomic features of the two groups. Excellent donors showed an enrichment in cytotoxicity pathways and a depletion of myeloid traits, linked to the presence of a larger population of effector-like NK cells early on during differentiation. Consequently, we defined a multi-factorial gene expression signature able to predict the donors' cytotoxic potential. Our study contributes to the identification of key traits of superior NK cell batches, supporting the development of efficacious NK therapeutics and the achievement of durable anti-tumor responses.

29 August 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SDStefania Douka
Stefania Douka
VPVasilis Papamoschou
Vasilis Papamoschou
MRMonica Raimo
Monica Raimo
Enrico MastrobattistaEnrico Mastrobattista
Enrico Mastrobattista
MCMassimiliano Caiazzo
Massimiliano Caiazzo
Natural killer (NK) cells have recently gained popularity as an alternative for cancer immunotherapy. Adoptive cell transfer employing NK cells offers a safer therapeutic option compared to T-cell-based therapies, due to their significantly lower toxicity and the availability of diverse autologous and allogeneic NK cell sources. However, several challenges are associated with NK cell therapies, including limited in vivo persistence, the immunosuppressive and hostile tumor microenvironment (TME), and the lack of effective treatments for solid tumors. To address these limitations, the modification of NK cells to stably produce cytokines has been proposed as a strategy to enhance their persistence and proliferation. Additionally, the overexpression of activating receptors and the blockade of inhibitory receptors can restore the NK cell functions hindered by the TME. To further improve tumor infiltration and the elimination of solid tumors, innovative approaches focusing on the enhancement of NK cell chemotaxis through the overexpression of chemotactic receptors have been introduced. This review highlights the latest advancements in preclinical and clinical studies investigating the engineering of activating, inhibitory, and chemotactic NK cell receptors; discusses recent progress in cytokine manipulation; and explores the potential of combining the chimeric antigen receptor (CAR) technology with NK cell receptors engineering.

25 June 2025 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
NKNina Kok
Nina Kok
ZDZoë Dekkers
Zoë Dekkers
ALAnica Loos
Anica Loos
TBThomas Bos
Thomas Bos
PBPuck van Den Broek
Puck van Den Broek
MRMonica Raimo
Monica Raimo
Background: Cell therapy is a promising field with the potential to improve outcomes for cancer and autoimmune disease patients. However, its complex and resource-intensive manufacturing requires costly infrastructure. Current processes, adapted from academic research, involve open handlings, manual processing, and repurposed equipment from biologics applications, raising quality and safety risks while increasing manufacturing costs. Closed, automated manufacturing systems can overcome these limitations.Methods: Allogeneic therapeutic natural killer (NK) cells can be generated from umbilical cord blood (UCB)-derived CD34+ hematopoietic stem cells in a closed, semi-automated process. Here, the automated CliniMACS Prodigy® system has been evaluated for reliability and performance in two unit operations, the enrichment of CD34+ stem cells from cord blood and the final product harvest and concentration. In this study, we report the outcome of these two processes across N = 36 different manufacturing runs performed during process development and GMP manufacturing for clinical release.Results: Efficiency of CD34+ stem cell enrichment was evaluated across cord blood units with low (7.00E06 CD34+ cells, N = 12) content. Robust performance was observed in all groups, with average CD34+ cell recoveries of 68.18%, 68.46%, and 71.94%, respectively. Higher purity was achieved in the high group (69.73%), compared to low (57.48%) and medium (62.11%). Factors such as UCB age, total nucleated cell count, and platelet or red blood cell content had no significant impact. For the final harvest and concentration process, we analyzed batches with low (5 L, N = 8). Approximatively 20% cell loss was reported, with average yields of 74.59% for low, 82.69% for medium, and 83.74% for high volumes. NK cell purity was stable at over 80%, and B and T cell impurities content remained low or undetectable.Discussion: This study presents an agile solution using a single piece of equipment during two steps of a complex NK cell manufacturing process. This approach ensures closed system safety, automation, high consistency, and cost-effectiveness, enabling the successful delivery of high-quality allogeneic NK cell therapies to patients.

17 January 2024 in Heliyon
Verified
Journal Article
Open access
MRMonica Raimo
Monica Raimo
AZAlexandra G. Zavoianu
Alexandra G. Zavoianu
WMWilma Meijs
Wilma Meijs
PSPascal Scholten
Pascal Scholten
JSJan Spanholtz
Jan Spanholtz
Natural Killer (NK) cell-based therapies represent a ground-breaking opportunity for the treatment of solid tumors and hematological malignancies. NK cell manufacturing under good manufacturing practice (GMP) is complex and requires attentive assessment the product's safety and efficacy through quality control (QC). Release testing includes monitoring of in vitro cell expansion, differentiation, purity, phenotype, and cytotoxicity. As NK cells are biologically active products, the establishment of potency methods is particularly relevant; surrogate or improper assays can lead to rejection of qualifiable batches or to release of products that falsely meet potency specifications, potentially causing low efficacy during clinical trials. As cell-based therapeutics are highly heterogeneous, no universal guidelines for product characterization are available, and developers must invest significant effort in establishing and validating robust and fit-to-purpose assays. In this study, we describe the qualification procedure of a flow cytometry-based analytical method to assess in vitro potency of GTA002 NK cells, to be applied to oNKord®/inaleucel allogeneic off-the-shelf NK cell product from Glycostem Therapeutics, undergoing a Phase I/IIa clinical trial in acute myeloid leukemia (AML) patients (NCT04632316). First, we established multi-color flow cytometry panels to quantitatively determine the count of effector (E) GTA002 cells and leukemia target (T) K562 cells alone and in co-culture at different E:T ratios (10:1, 3:1, 1:1). Effector potency was then qualitatively expressed as percentage of cytotoxicity. Next, we defined protocols for method qualification to assess the pivotal features of the assays, including accuracy, precision, linearity, range, specificity, robustness, and carryover; quantitative acceptance criteria were determined for all parameters. Results of the qualification procedure are reported and discussed against pre-defined acceptance criteria. Overall, our methods show robust performance across all parameters, ensuring QC-compliant assessment of NK cell potency as part of the release test panel for clinical batches. Notably, we identified relevant aspects to address when progressing towards method validation to support pivotal clinical studies. This article provides a “case-study” of how analytical method development for cell therapeutics is planned and executed from early clinical stages, anticipating the need to establish robust procedures to overcome scientific and regulatory challenges during method validation.